홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
ITRM
#3825
Iterum Therapeutics plc Ordinary Share
0.2
6
+13.04%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
+13.04%
월간 변동
-21.21%
6달 변화
-63.38%
년간 변동율
-80.60%
이전 종가
0.2
3
Open
0.2
6
Bid
Ask
Low
0.2
6
High
0.2
6
양
2
마켓
주식
헬스케어
ITRM
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
11.77 M
12.19 M
12.71 M
16.43 M
34.58 M
—
Valuation ratios
Enterprise value
—
—
-9.4 M
26.37 M
37.08 M
—
Price to earnings ratio
—
—
-0.25
-0.67
-1.4
-4.91
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
—
—
-0.61
-0.65
-1.3
-5.47
Price to book ratio
—
—
0.4
-4
-8.54
-11.42
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
1.59
1
0.66
1.46
0.56
0.76
Return on equity %
1.03
1.82
1.59
5.99
6.07
6.42
Return on invested capital %
354.99
284.57
960.67
4 974.98
420.29
390.3
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
0.51
6.43
6.89
1.89
1.41
9.46
Current ratio
0.51
6.43
6.89
1.89
1.41
9.96
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0.68
0.08
0.15
0.44
0.7
2.52
Long term debt to total equity ratio
0.44
0.14
0.36
1.79
7.65
23.41
Per share metrics
Operating cash flow per share
—
—
1.51
3.03
1.36
0.59
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
4.97
1.85
1.22
2.16
Net current asset value per share
—
—
5.1
1.97
1.26
2.33
Tangible book value per share
—
—
2.15
0.49
-0.8
-1.92
Working capital per share
—
—
4.36
0.93
0.36
1.05
Book value per share
—
—
2.29
0.49
0.21
0.54
뉴스
이테룸 테라퓨틱스, ORLYNVAH® Medicare Part D 접근성 확대
Iterum Therapeutics expands Medicare Part D access for ORLYNVAH
Iterum Therapeutics expands market access for ORLYNVAH antibiotic
이테룸 테라퓨틱스, 주요 PBM 계약 체결
Iterum Therapeutics secures major PBM agreement for antibiotic
Iterum, 나스닥 상장 요건 미달 통보 받아
Iterum Therapeutics receives Nasdaq notice on listing compliance
이테룸 테라퓨틱스, ORLYNVAH 보험 적용 범위 확대
Iterum Therapeutics expands reimbursement coverage for ORLYNVAH
Iterum’s antibiotic ORLYNVAH now available through McKesson
Iterum 치료제 이사, 2,191달러 상당 주식 매입
Iterum Therapeutics director Dunne buys $2,191 in shares